Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1395 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.000221 | uM | 7813.007 | 1.0474 | 1.1140 | 0.8361 | |
| HCC1395 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.0011 | uM | 7813.007 | 0.9275 | 0.8278 | 0.8361 | |
| HCC1395 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.00552 | uM | 7813.007 | 1.0190 | 1.0455 | 0.8361 | |
| HCC1395 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.0276 | uM | 7813.007 | 1.0861 | 1.2076 | 0.8361 | |
| HCC1395 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.138 | uM | 7813.007 | 1.1091 | 1.2637 | 0.8361 | |
| HCC1395 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.69 | uM | 7813.007 | 0.6550 | 0.2058 | 0.8361 | |
| HCC1395 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 3.45 | uM | 7813.007 | 0.3365 | -0.4564 | 0.8361 | |
| HCC1395 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 17.2 | uM | 7813.007 | 0.1318 | -0.8228 | 0.8361 | |
| HCC1395 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 86.2 | uM | 7813.007 | 0.0532 | -0.9401 | 0.8361 | |
| HCC1395 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.000221 | uM | 7816.007 | 1.0371 | 1.0641 | 1.1536 | |
| HCC1395 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.0011 | uM | 7816.007 | 0.8428 | 0.7245 | 1.1536 | |
| HCC1395 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.00552 | uM | 7816.007 | 0.9873 | 0.9779 | 1.1536 | |
| HCC1395 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.0276 | uM | 7816.007 | 2.0444 | 2.7173 | 1.1536 | |
| HCC1395 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.138 | uM | 7816.007 | 0.7434 | 0.5468 | 1.1536 | |
| HCC1395 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.69 | uM | 7816.007 | 0.6623 | 0.3993 | 1.1536 | |
| HCC1395 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 3.45 | uM | 7816.007 | 0.8361 | 0.7125 | 1.1536 | |
| HCC1395 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 17.2 | uM | 7816.007 | 0.6185 | 0.3187 | 1.1536 | |
| HCC1395 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 86.2 | uM | 7816.007 | 1.5915 | 1.9920 | 1.1536 | |
| HCC1395 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.000236 | uM | 9254.121 | 1.0501 | 1.0808 | 1.2352 | |
| HCC1395 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.00118 | uM | 9254.121 | 0.9929 | 0.9885 | 1.2352 | |
| HCC1395 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.00589 | uM | 9254.121 | 1.0595 | 1.0958 | 1.2352 | |
| HCC1395 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.0294 | uM | 9254.121 | 0.9716 | 0.9539 | 1.2352 | |
| HCC1395 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.147 | uM | 9254.121 | 0.7416 | 0.5700 | 1.2352 | |
| HCC1395 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.736 | uM | 9254.121 | 0.5242 | 0.1857 | 1.2352 | |
| HCC1395 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 3.68 | uM | 9254.121 | 0.2639 | -0.3198 | 1.2352 |